Immune Signature Links to Preterm Birth Risk
Pregnant women may want to know that this maternal antibody pattern appears in preterm pregnancies, though it is not yet a clinical test.
Updated on Nov. 6, 2026 in Pregnancy

Researchers have identified a broad maternal autoantibody signature associated with preterm delivery, with the immune-reactivity pattern diverging from term pregnancies as early as the first trimester. The findings may eventually inform risk assessment for women who are pregnant or planning pregnancy.
Why it matters
Preterm birth remains a leading contributor to newborn complications, and this work points to immune signals that appear well before delivery rather than only in its final weeks. Recognizing these patterns could in future shape how clinicians think about prevention and monitoring, though the findings are not yet a clinical test.
This comparative study examined maternal autoantibody profiles in term and preterm pregnancies, identifying a signature with 9,209 peptide reactivities across 3,594 proteins. Reactivity was higher in deliveries before 28 weeks and in women with four or more prior pregnancies, but the source does not report sample size, effect size, or whether the findings have been validated in independent cohorts.
The details
The reactivities target proteins involved in hormone signalling, placental angiogenesis, tissue remodelling, HLA molecules, and cytokines, all of which play roles in building and maintaining the placenta during pregnancy. The breadth of this immune signature grows in the weeks before preterm delivery, and the authors also identified autoantibodies targeting IL-1 receptor antagonist, which related work has linked to inflammatory and vascular pathology in pregnancy.
Timeline
First trimester: the autoreactive signature begins to diverge from that of term pregnancies.
Weeks preceding preterm delivery: the breadth of the autoreactive signature increases.
Before 28 weeks: deliveries show greater autoantibody reactivity than later preterm deliveries.
Health Landscape
Preterm birth has long been studied largely through obstetric and infectious risk factors, and the identification of a broad maternal autoimmune signature shifts attention toward immune processes that begin early in pregnancy. The work sits within a growing body of research testing whether maternal immunology can explain part of the variation in preterm outcomes.
If you are pregnant or planning a pregnancy, this research is a reminder that preterm birth has biological roots that begin early, so it is worth discussing your personal risk factors, including your number of prior pregnancies, with your obstetrician or midwife. No test or action based on this autoantibody signature is established yet, so continue following your care team's current prenatal guidance.
The takeaway
Preterm birth may have immune signals detectable well before delivery, and the study suggests the process can start as early as the first trimester. Keep up with routine prenatal visits and bring any questions about your pregnancy history to your care team.
Further reading
For broader context on how immune changes shape pregnancy outcomes, explore our Pregnancy coverage.
Source note: This article includes information reported by Nature.


